EUVIMEDEUVIMED entdecken
Open Access

Global Trend of MASH-associated Liver Cancer: A Systematic Analysis From the Global Burden of Disease 2021

Pojsakorn Danpanichkul, Kanokphong Suparan, Chuthatip Kaeosri, Pimtawan Jatupornpakdee, Abdelrahman M Attia, Thanathip Suenghataiphorn, Jerapas Thongpiya, Banthoon Sukphutanan, Daniel Q Huang, Mazen Noureddin, Amit G Singal, Karn Wijarnpreecha und 1 weitere

Clinical Gastroenterology and Hepatology · 2025

DOI: 10.1016/j.cgh.2024.10.026 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Gastroenterology and Hepatology, 2025. Verfasst von Pojsakorn Danpanichkul und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Texas Tech University Health Sciences Center, Lubbock, Texas. Hauptthemen laut MEDLINE: Global Burden of Disease, Liver Neoplasms. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Cancer Institute, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND & AIMS: Metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) are the leading causes of liver disease and are emerging as the main risk factors for primary liver cancer (PLC). However, updated global data on MASH remain scarce. METHODS: This study analyzed data from the Global Burden of Disease study between 2000 and 2021 to assess the age-standardized incidence, mortality, and disability-adjusted life years (DALYs) from MASH-associated PLC, stratified by geographical region, sociodemographic index, age, and sex. RESULTS: There were 42,290 incident cases, 40,920 deaths, and 995,470 DALYs from PLC globally. Global incidence (+98%), death (+93%), and DALYs (+76%) from MASH-associated PLC increased steeply over the study period. Among different etiologies, only MASH-associated PLC had increased mortality rates (annual percent change [APC], +0.46; 95% confidence interval [CI], 0.33%-0.59%). Africa and low sociodemographic index countries exhibited the highest age-standardized incidence, death, and DALYs from MASH-associated PLC. DALYs increased in females (APC, 0.24%; 95% CI, 0.06%-0.42%), whereas they remained stable in males. Americas experienced the highest percentage increase in age-standardized incidence rate (APC, 2.09%; 95% CI, 2.02%-2.16%), age-standardized death rate (APC, 1.96%; 95% CI, 1.69%-2.23%), and age-standardized DALYs (APC, 1.96%; 95% CI, 1.63%-2.30%) from MASH-associated PLC. CONCLUSIONS: Over the past 2 decades, the burden of MASH-associated PLC has risen, though there are sociodemographic and geographic disparities. This necessitates urgent strategies across the globe to mitigate the epidemic of MASH-associated PLC as well as its metabolic drivers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Global Burden of DiseaseLiver NeoplasmsHumansMaleFemaleIncidenceMiddle AgedDisability-Adjusted Life YearsAdultAgedRisk FactorsGlobal Health

Stichwörter der Autor:innen

CancerEpidemiologyLiver CancerMetabolic Dysfunction-associated Steatotic Liver DiseaseNonalcoholic Fatty Liver Disease

Autor:innen und Institutionen

  • Department of Internal Medicine, Texas Tech University Health Sciences Center, Lubbock, Texas.
  • Immunology Unit, Department of Microbiology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
  • Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
  • Karsh Division of Gastroenterology and Hepatology, Comprehensive Transplant Center, and Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California.
  • Department of Internal Medicine, Griffin Hospital, Derby, Connecticut.
  • Division of Gastroenterology and Hepatology, Department of Medicine, National University Health System, Singapore, Singapore.

Förderung

  • NCI NIH HHS
  • National Cancer Institute
  • National Institutes of Health

Zitieren

APA

Danpanichkul, P., Suparan, K., Kaeosri, C., Jatupornpakdee, P., Attia, A. M., Suenghataiphorn, T., Thongpiya, J., Sukphutanan, B., Huang, D. Q., Noureddin, M., Singal, A. G., Wijarnpreecha, K., & Yang, J. D. (2025). Global Trend of MASH-associated Liver Cancer: A Systematic Analysis From the Global Burden of Disease 2021. Clinical Gastroenterology and Hepatology. https://doi.org/10.1016/j.cgh.2024.10.026

Vancouver

Danpanichkul P, Suparan K, Kaeosri C, Jatupornpakdee P, Attia AM, Suenghataiphorn T, et al. Global Trend of MASH-associated Liver Cancer: A Systematic Analysis From the Global Burden of Disease 2021. Clinical Gastroenterology and Hepatology. 2025. doi:10.1016/j.cgh.2024.10.026

BibTeX
@article{Danpanichkul2025,
  author = {Danpanichkul, Pojsakorn and Suparan, Kanokphong and Kaeosri, Chuthatip and Jatupornpakdee, Pimtawan and Attia, Abdelrahman M and Suenghataiphorn, Thanathip and Thongpiya, Jerapas and Sukphutanan, Banthoon and Huang, Daniel Q and Noureddin, Mazen and Singal, Amit G and Wijarnpreecha, Karn and Yang, Ju Dong},
  title = {Global Trend of MASH-associated Liver Cancer: A Systematic Analysis From the Global Burden of Disease 2021},
  journal = {Clinical Gastroenterology and Hepatology},
  year = {2025},
  doi = {10.1016/j.cgh.2024.10.026}
}
Kostenlos starten →